Analysis of the mechanism of HCMV cytoplasmic envelopment

HCMV胞质包膜机制分析

基本信息

项目摘要

Although largely asymptomatic, human cytomegalovirus (HCMV) can cause severe and even fatal disease in a subset of susceptible individuals. While great progress has been made in understanding essential stages of HCMV replication, a detailed description of many of these processes is lacking. Of particular interest in this proposal is the maturation of HCMV virions, namely tegument acquisition and cytoplasmic envelopment. To provide a molecular description of these events, it is important to identify the factors involved, both viral and cellular. This proposal will focus on two viral proteins, UL88 and UL71. We have previously published a role for UL88 in packaging a subset of tegument proteins into the virion tegument layer and the absence of UL88 decreases viral fitness. Previous work has identified UL71 as an envelopment factor that potentially mediates membrane scission, as viruses lacking UL71 are trapped at various stages of budding. The experiments in this proposal will seek to elucidate the molecular details of how UL88 and UL71 drive tegument acquisition and envelopment, respectively. This includes a detailed analysis of functional regions on each protein as well as an investigation into additional factors that potentially contribute to each process. We will investigate the role of EEA1+ endosomes in tegument acquisition and for the membrane scission factor DNM1 in cytoplasmic envelopment. This proposal will utilize a novel fluorescence-based envelopment to identify additional cellular proteins that participate in envelopment. Taken together, these studies will further our understanding of the molecular events that drive the late stages of HCMV maturation and identify novel ways in which HCMV assembly can be targeted as a potential intervention.
虽然人类巨细胞病毒(HCMV)在很大程度上是无症状的,但它可以在一部分易感人群中引起严重甚至致命的疾病。虽然在理解巨细胞病毒复制的关键阶段方面取得了很大进展,但对其中许多过程缺乏详细的描述。在这项提议中特别感兴趣的是人巨细胞病毒病毒粒子的成熟,即被膜的获取和细胞质的包膜。为了提供这些事件的分子描述,重要的是确定涉及的因素,包括病毒和细胞。该提案将重点关注两种病毒蛋白UL88和UL71。我们之前已经发表了UL88在将被膜蛋白的子集包装到病毒粒子被膜层中的作用,而UL88的缺失会降低病毒的适合性。以前的工作已经确定UL71是一个潜在的介导膜破裂的包膜因子,因为缺乏UL71的病毒被困在萌芽的不同阶段。本方案中的实验将试图阐明UL88和UL71分别如何驱动被膜获取和包膜的分子细节。这包括对每种蛋白质功能区域的详细分析,以及对可能影响每一过程的其他因素的调查。我们将研究EEA1+内体在被膜获取中的作用,以及细胞质被膜中膜断裂因子DNM1的作用。这项提议将利用一种新的基于荧光的包膜来识别参与包膜的其他细胞蛋白质。综上所述,这些研究将进一步加深我们对驱动HCMV成熟后期的分子事件的理解,并确定将HCMV组装作为潜在干预的新方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Christopher C Norbury其他文献

Christopher C Norbury的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Christopher C Norbury', 18)}}的其他基金

How does Cytomegalovirus use interferon lambda for optimal spread
巨细胞病毒如何利用 lambda 干扰素实现最佳传播
  • 批准号:
    10552002
  • 财政年份:
    2022
  • 资助金额:
    $ 48.76万
  • 项目类别:
The effect of local virus infection upon cutaneous wound healing: the impact of virus-induced Type III IFNs
局部病毒感染对皮肤伤口愈合的影响:病毒诱导的III型干扰素的影响
  • 批准号:
    10433972
  • 财政年份:
    2021
  • 资助金额:
    $ 48.76万
  • 项目类别:
The effect of local virus infection upon cutaneous wound healing: the impact of virus-induced Type III IFNs
局部病毒感染对皮肤伤口愈合的影响:病毒诱导的III型干扰素的影响
  • 批准号:
    10217681
  • 财政年份:
    2021
  • 资助金额:
    $ 48.76万
  • 项目类别:
Interferon-independent STAT1-mediated protective antiviral immunity
不依赖干扰素的STAT1介导的保护性抗病毒免疫
  • 批准号:
    9378819
  • 财政年份:
    2017
  • 资助金额:
    $ 48.76万
  • 项目类别:
The Toponome of Virus Infected Skin
病毒感染皮肤的地形图
  • 批准号:
    9186754
  • 财政年份:
    2016
  • 资助金额:
    $ 48.76万
  • 项目类别:
Poxviruses and Pro-Resolving Lipids
痘病毒和促溶解脂质
  • 批准号:
    8808629
  • 财政年份:
    2014
  • 资助金额:
    $ 48.76万
  • 项目类别:
Viral Manipulation of Myeloid Cell Function
病毒操纵骨髓细胞功能
  • 批准号:
    8450749
  • 财政年份:
    2012
  • 资助金额:
    $ 48.76万
  • 项目类别:
Viral Manipulation of Myeloid Cell Function
病毒操纵骨髓细胞功能
  • 批准号:
    8226379
  • 财政年份:
    2012
  • 资助金额:
    $ 48.76万
  • 项目类别:
Histology and Imaging Core
组织学和成像核心
  • 批准号:
    7746214
  • 财政年份:
    2009
  • 资助金额:
    $ 48.76万
  • 项目类别:
Processing & Presentation of Ectromelia Virus to CD4+ T Lymphocytes - Asso Projec
加工
  • 批准号:
    7982871
  • 财政年份:
    2009
  • 资助金额:
    $ 48.76万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 48.76万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 48.76万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 48.76万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 48.76万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 48.76万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 48.76万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 48.76万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 48.76万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 48.76万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 48.76万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了